I don't need any convincing. I first bought in on the upswing (like an idiot, breaking my own rule) at .012 based on your DD and Jay's DD on the other board. I liked that the goals of the company were clear, concise, and to in progress. I researched the board of doctors and felt confident this team could get past at least Phase I.

Just looking forward to the ride once approval to conduct initial trials begins. I think your post on approval rate is good, but do those numbers reflect orphan drug designation? I know it allows them to accelerate through Phase II/III, which would reduce the costs/timeline significantly.